Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors

PURPOSE: Our preclinical work identified depletion of ATR as a top candidate for topoisomerase 1 (TOP1) inhibitor synthetic lethality and showed that ATR inhibition sensitizes tumors to TOP1 inhibitors. We hypothesized that a combination of selective ATR inhibitor M6620 (previously VX-970) and topot...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Thomas, Anish, Redon, Christophe E., Sciuto, Linda, Padiernos, Emerson, Ji, Jiuping, Lee, Min-Jung, Yuno, Akira, Lee, Sunmin, Zhang, Yiping, Tran, Lan, Yutzy, William, Rajan, Arun, Guha, Udayan, Chen, Haobin, Hassan, Raffit, Alewine, Christine C., Szabo, Eva, Bates, Susan E., Kinders, Robert J., Steinberg, Seth M., Doroshow, James H., Aladjem, Mirit I., Trepel, Jane B., Pommier, Yves
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2018
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5978471/
https://ncbi.nlm.nih.gov/pubmed/29252124
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.76.6915
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados